Daiichi Sankyo Company, Limited (DSKYF) は上場企業です ヘルスケア セクターの 製薬 業界で事業展開. 本社所在地は Tokyo, 日本. 現CEOは Hiroyuki Okuzawa.
DSKYF を有する IPO日 2008-06-24, 18,726 名の正社員, に上場 Other OTC, 時価総額 $32.23B.
Daiichi Sankyo Company, Limited is a Tokyo-based pharmaceutical company founded in 1899 that researches, develops, manufactures, and markets a diverse portfolio of prescription and over-the-counter medicines globally. The company's core therapeutic areas include oncology, cardiovascular disease, diabetes, pain management, and infectious disease, with key products such as Enhertu (trastuzumab deruxtecan) for cancer treatment, edoxaban for anticoagulation, and teneligliptin for diabetes management. Beyond pharmaceuticals, Daiichi Sankyo operates across consumer health, vaccines, animal health, cosmetics, and medical devices. The company has established strategic collaborations, including a partnership with Guardant Health to develop companion diagnostics, and maintains a strong commitment to innovation across multiple healthcare segments.
